(1) HPV, the human papillomavirus, is the 
most common sexually transmitted infection in the 
United States. HPV types 16 and 18 cause about 70 
percent of cervical cancers. The Centers for Disease 
Control and Prevention estimates that about 
6,200,000 Americans become infected with HPV 
each year and that over half of all sexually active 
men and women become infected at some time in 
their lives. On average, there are 9,710 new cases of 
cervical cancer and 3,700 deaths attributed to it in 
the United States each year. 
(2) Early detection is the key to diagnosing and 
curing cervical cancer, and therefore the Food and 
Drug Administration (FDA) recommends that all 
women get regular Pap tests. The Pap test looks for 
cell changes caused by HPV, so the cervix can be 
treated before the cells turn into cancer. The FDA 
also states the Pap test can also find cancer in its 
early stages so it can be treated before it becomes 
too serious, and reaches the conclusion that it is 
rare to die from cervical cancer if the disease is 
caught early. 
(3) On June 8, 2006, the FDA approved 
Gardasil, the first vaccine developed to prevent cer-
vical cancer, precancerous genital lesions, and gen-
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1153.IH
H1153
jcorcoran on PROD1PC62 with BILLS
ital warts due to human papillomavirus (HPV) types 
6, 11, 16, and 18. Gardasil is a recombinant vac-
cine, it does not contain a live virus, and it is given 
as three injections over a six-month period. The vac-
cine is approved for use in females 9–26 years of 
age. However, the FDA also states that since the 
vaccine is new, more studies need to be done to de-
termine how long women will be protected from 
HPV. For example, the FDA does not know if a 
booster is needed after a couple of years to ensure 
continuity of protection. 
(4) As detailed by the FDA, four studies were 
conducted in 21,000 women, one in the United 
States and three multinational, to show how well 
Gardasil worked in women between the ages of 16 
and 26. The study period was not long enough for 
cervical cancer to develop; however, preventing cer-
vical precancerous lesions is believed highly likely to 
result in the prevention of cervical cancer. 
(5) In January 2007 the Advisory Committee 
on Immunization Practices (ACIP), under the Cen-
ters for Disease Control and Prevention, issued 
changes to the previous childhood and adolescent im-
munization schedule. The ACIP recommends the 
new human papillomavirus vaccine (HPV) to be ad-
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1153.IH
H1153
jcorcoran on PROD1PC62 with BILLS
ministered in a 3-dose schedule with the second and 
third doses administered 2 and 6 months after the 
first dose. Routine vaccination with HPV is rec-
ommended for females aged 11–12 years, the vac-
cination series can be started in females as young as 
age 9 years, and a catch up vaccination is rec-
ommended for females aged 13–26 years who have 
not been vaccinated previously or who have not com-
pleted the full vaccine series. 
(6) States historically have maintained the 
practice of applying immunization recommendations 
to their school admittance policies so as to protect 
schoolchildren from outbreaks of contagious disease. 
The Association of American Physicians and Sur-
geons states that there is no public health purpose 
for mandating HPV vaccine for schoolchildren. HPV 
is a sexually transmitted disease. 
(7) With at least 16 States entertaining legisla-
tion which takes the unprecedented step in requiring 
young girls to obtain a vaccine for a disease that is 
not spread by casual contact in order to attend 
school, many organizations and associations have 
come out against mandatory HPV vaccine programs. 
(8) The Texas Medical Association has stated 
that although it strongly supports the ability of phy-
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1153.IH
H1153
jcorcoran on PROD1PC62 with BILLS
sicians to provide the HPV vaccine, at this point, it 
does not support a State mandate. 
(9) The American College of Pediatricians and 
the Association of American Physicians and Sur-
geons are opposed to any legislation which would re-
quire HPV vaccination for school attendance. They 
have stated that excluding children from school for 
refusal to be vaccinated for a disease spread only by 
intercourse is a serious, precedent-setting action that 
trespasses on the right of parents to make medical 
decisions for their children as well as on the rights 
of the children to attend school. 
(10) Federal funds should not be used to imple-
ment a mandatory vaccine program for a disease 
that does not threaten the public health of school-
children in the course of casual, daily interaction be-
tween classmates and inserts the government into 
the lives of children, parents, and physicians. 
SEC. 3. PROHIBITION AGAINST FUNDING FOR MANDATORY 
HUMAN PAPILLOMAVIRUS (HPV) VACCINA-
TION PROGRAMS. 
No Federal funds or other assistance may be made 
available to any State or political subdivision of a State 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1153.IH
H1153
jcorcoran on PROD1PC62 with BILLS
to establish or implement any requirement that individuals 
receive vaccination for human papillomavirus (HPV). 
Æ 
VerDate Aug 31 2005 
04:34 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H1153.IH
H1153
jcorcoran on PROD1PC62 with BILLS